Dr. Gregory Andrew Durm, MD

Dr. Durm practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Durm's NPI, 1316172299, was assigned on May 21, 2009. Dr. Durm holds Indiana license 01070705A.

Dr. Durm's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Durm's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Durm is also affiliated with IU Health Ball Memorial Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Durm to 3 more hospitals, 2 group practices and clinics, 1 behavioral health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Durm practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Durm's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Durm is licensed in Indiana.

CMS data shows 326 Medicare services from Dr. Durm across 6 procedure codes in 2024, for 120 Medicare patients. Medicare paid $25,117 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 120 Medicare patients who saw Dr. Durm in 2024. The largest group is 65 to 74, with 62 patients. 74% of them have high blood pressure, and 68% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Durm's median patient age at 65, with 40% women.

In 2024, Dr. Durm wrote 734 Medicare Part D claims for 94 patients. 74% of them were for generic drugs. CMS names the drug for 532 of them, across 21 drugs with 11 or more claims each, at $1,391,346 in total drug cost. In 2023, CMS named 372 claims across 19 drugs.

Dr. Durm accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Durm as offering telehealth.

Dmand AI links 14 papers to Dr. Durm, published from 2019 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Cell Line, Tumor and Medical Oncology. Dr. Durm has published most often in J Control Release. Dr. Durm's most frequent co-authors are Shadia I. Jalal, MD, Lawrence H. Einhorn, MD and Mark P. Langer, MD.

Dmand AI links Dr. Durm to 2 clinical trials. Conditions studied include Rectal Diseases and Colorectal Neoplasms. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Durm that name 1 trial.

CMS Open Payments shows 25 general payments to Dr. Durm from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Daiichi Sankyo Inc. paid the most, $9,518. It also lists 2 research payments totaling $11,174 in 2020, naming 1 clinical trial.